Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07562152 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

510

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer
Pancreatic Cancer Metastatic
PDAC
PDAC - Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Pancreatic Adenocarcinoma Metastatic
Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic Adenocarcinoma

Interventions

DRUG: Atebimetinib
DRUG: GnP
DRUG: mGnP

Sponsor

Immuneering Corporation